Abbreviations |
|
xxv | |
|
1 Introduction And Historical Background |
|
|
1 | (40) |
|
|
1 | (2) |
|
1.2 Definitions and nomenclature |
|
|
3 | (12) |
|
|
3 | (2) |
|
1.2.2 Some additional adjectival polymorphisms: pros and cons |
|
|
5 | (2) |
|
1.2.3 Pseudopolymorphism, solvates, and hydrates |
|
|
7 | (4) |
|
1.2.4 Conventions for naming polymorphs |
|
|
11 | (4) |
|
1.3 Is this material polymorphic? |
|
|
15 | (15) |
|
1.3.1 Occurrence of polymorphism |
|
|
15 | (5) |
|
1.3.2 Literature sources of polymorphic compounds |
|
|
20 | (6) |
|
1.3.3 Polymorphic compounds in the Cambridge Structural Database |
|
|
26 | (2) |
|
1.3.4 Powder Diffraction File |
|
|
28 | (1) |
|
|
28 | (1) |
|
1.3.6 Polymorphism of elements and inorganic compounds |
|
|
29 | (1) |
|
1.3.7 Polymorphism in macromolecular crystals |
|
|
29 | (1) |
|
1.4 Historical perspective |
|
|
30 | (9) |
|
1.5 Commercial/industrial importance of polymorphism---some additional comments |
|
|
39 | (2) |
|
|
41 | (37) |
|
|
41 | (1) |
|
2.2 The thermodynamics of molecular crystals |
|
|
41 | (14) |
|
|
42 | (1) |
|
2.2.2 Thermodynamic relations in polymorphs |
|
|
43 | (2) |
|
2.2.3 Energy versus temperature diagrams---the Gibbs free energy |
|
|
45 | (2) |
|
2.2.4 Enantiotropism and monotropism |
|
|
47 | (1) |
|
2.2.5 Phase diagrams in terms of pressure and temperature |
|
|
47 | (5) |
|
2.2.6 Heat-of-transition rule |
|
|
52 | (1) |
|
2.2.7 Heat-of-fusion rule |
|
|
52 | (1) |
|
2.2.8 Entropy-of-fusion rule |
|
|
53 | (1) |
|
|
53 | (1) |
|
|
53 | (1) |
|
|
54 | (1) |
|
2.3 Kinetic factors determining the formation of polymorphic modifications |
|
|
55 | (3) |
|
2.4 Structural fundamentals |
|
|
58 | (18) |
|
|
59 | (4) |
|
2.4.2 Structural characterization and comparison of polymorphic systems |
|
|
63 | (13) |
|
2.5 Thermodynamics and kinetics of crystallization---signs of a changing paradigm |
|
|
76 | (2) |
|
3 Exploring The Crystal Form Landscape |
|
|
78 | (58) |
|
3.1 General considerations |
|
|
79 | (1) |
|
3.2 Aggregation and nucleation |
|
|
79 | (8) |
|
3.3 Thermodynamic versus kinetic crystallization conditions |
|
|
87 | (2) |
|
3.4 Monotropism, enantiotropism, and crystallization strategy |
|
|
89 | (1) |
|
3.5 The polymorph (solid form) screen |
|
|
90 | (24) |
|
|
90 | (3) |
|
3.5.2 When to carry out a solid form screen? |
|
|
93 | (1) |
|
3.5.3 What comprises a solid form screen? |
|
|
94 | (8) |
|
3.5.4 What is the time frame for a solid form screen? |
|
|
102 | (3) |
|
3.5.5 What are the variables in a crystallization? |
|
|
105 | (1) |
|
3.5.6 High throughput (HT) screening for solid forms |
|
|
105 | (4) |
|
3.5.7 A specific example of a solid form screen---axitinib |
|
|
109 | (5) |
|
3.6 Concomitant polymorphs |
|
|
114 | (17) |
|
3.6.1 Concomitant polymorphs---crystallization methods and conditions |
|
|
115 | (5) |
|
3.6.2 Concomitant polymorphs---examples of different classes of compounds |
|
|
120 | (8) |
|
3.6.3 Concomitant polymorphs---the structural approach |
|
|
128 | (3) |
|
3.7 Disappearing polymorphs |
|
|
131 | (4) |
|
|
135 | (1) |
|
4 Analytical Techniques For Studying And Characterizing Polymorphs And Polymorphic Transitions |
|
|
136 | (79) |
|
|
136 | (1) |
|
4.2 Optical/hot stage microscopy |
|
|
137 | (9) |
|
|
146 | (9) |
|
4.4 X-ray crystallography |
|
|
155 | (14) |
|
4.5 Infrared spectroscopy |
|
|
169 | (7) |
|
|
176 | (5) |
|
4.7 Solid-state nuclear magnetic resonance (SSNMR) spectroscopy |
|
|
181 | (13) |
|
|
194 | (13) |
|
4.9 Atomic force microscopy (AFM) and scanning tunneling microscopy (STM) |
|
|
207 | (1) |
|
4.10 Density measurements |
|
|
207 | (1) |
|
4.11 New technologies and "hyphenated techniques" |
|
|
208 | (1) |
|
4.12 Are two samples polymorphs of the same compound? |
|
|
209 | (2) |
|
|
211 | (4) |
|
5 Computational Aspects Of Polymorphism |
|
|
215 | (58) |
|
|
215 | (1) |
|
5.2 Molecular shape and energetics |
|
|
216 | (1) |
|
5.3 Intermolecular interactions and energetics |
|
|
217 | (3) |
|
5.4 Presenting and comparing polymorphs |
|
|
220 | (1) |
|
5.5 Some early examples of conformational polymorphism |
|
|
221 | (5) |
|
5.6 What are conformational polymorphs good for? |
|
|
226 | (1) |
|
5.7 Computational studies of the energetics of polymorphic systems |
|
|
226 | (3) |
|
5.8 Some exemplary studies of conformational polymorphism |
|
|
229 | (8) |
|
5.9 The computational prediction of polymorphs |
|
|
237 | (10) |
|
|
237 | (3) |
|
5.9.2 Subsequent activity |
|
|
240 | (7) |
|
5.10 The computational comparison of polymorphs |
|
|
247 | (26) |
|
|
247 | (1) |
|
5.10.2 Comparison based on geometry criteria |
|
|
247 | (1) |
|
5.10.3 Comparison of crystal structures using Hirshfeld surfaces |
|
|
248 | (9) |
|
5.10.4 Conformational polymorphs |
|
|
257 | (10) |
|
5.10.5 Comparison of energetic environment |
|
|
267 | (1) |
|
5.10.6 Partitioning of lattice energy |
|
|
268 | (2) |
|
5.10.7 Comparison of X-ray powder diffraction patterns |
|
|
270 | (3) |
|
6 Polymorphism And Structure---Property Relations |
|
|
273 | (69) |
|
|
273 | (1) |
|
|
274 | (47) |
|
6.2.1 Electrical conductivity |
|
|
274 | (11) |
|
6.2.2 Organic magnetic materials |
|
|
285 | (8) |
|
6.2.3 Photovoltaicity and photoconductivity |
|
|
293 | (3) |
|
6.2.4 Nonlinear optical activity and second harmonic generation |
|
|
296 | (7) |
|
6.2.5 Chromoisomerism, photochromism, thermochromism, mechanochromism, etc. |
|
|
303 | (16) |
|
6.2.6 The thermo-photo-mechanosalient effect---"hopping" or "jumping" crystals |
|
|
319 | (1) |
|
6.2.7 Other physical properties |
|
|
320 | (1) |
|
|
321 | (11) |
|
6.3.1 Infrared and Raman spectroscopy |
|
|
321 | (2) |
|
6.3.2 UV/vis absorption spectroscopy |
|
|
323 | (7) |
|
|
330 | (1) |
|
6.3.4 Excited state diffraction studies |
|
|
331 | (1) |
|
6.4 Photochemical reactions |
|
|
332 | (3) |
|
6.5 Thermal reactions and gas--solid reactions |
|
|
335 | (1) |
|
|
336 | (1) |
|
6.7 A variety of emission phenomena |
|
|
337 | (4) |
|
|
341 | (1) |
|
7 Polymorphism Of Pharmaceuticals |
|
|
342 | (34) |
|
|
342 | (2) |
|
7.2 Occurrence of polymorphism in pharmaceuticals |
|
|
344 | (1) |
|
7.3 Importance of polymorphism in pharmaceuticals |
|
|
345 | (8) |
|
7.3.1 Dissolution rate and solubility |
|
|
346 | (1) |
|
|
346 | (5) |
|
7.3.3 Following phase changes and mixtures of forms |
|
|
351 | (2) |
|
7.4 Screening for crystal forms |
|
|
353 | (6) |
|
|
354 | (1) |
|
7.4.2 Screening specifically for hydrates and solvates |
|
|
355 | (1) |
|
|
356 | (1) |
|
7.4.4 Use of ionic liquids |
|
|
356 | (1) |
|
7.4.5 Obtaining a difficult stable or unstable new form |
|
|
357 | (1) |
|
7.4.6 New techniques and conditions |
|
|
358 | (1) |
|
7.5 Polymorphism in pharmaceutical co-crystals |
|
|
359 | (1) |
|
7.6 Chemical similarity is not a predictor of similar polymorphic behavior |
|
|
360 | (3) |
|
|
363 | (1) |
|
7.8 Microscopy and thermomicroscopy of pharmaceuticals |
|
|
364 | (1) |
|
7.9 Thermal analysis of pharmaceuticals |
|
|
365 | (2) |
|
7.10 The importance of metastable forms |
|
|
367 | (3) |
|
7.11 The importance of amorphous forms |
|
|
370 | (2) |
|
7.12 Obtaining a difficult stable or unstable new form |
|
|
372 | (2) |
|
|
374 | (2) |
|
8 Polymorphism Of Pigments And Dyes |
|
|
376 | (22) |
|
|
376 | (2) |
|
8.2 Occurrence of polymorphism among pigments |
|
|
378 | (6) |
|
8.3 Polymorphism in some specific groups of pigments |
|
|
384 | (11) |
|
|
384 | (2) |
|
|
386 | (2) |
|
|
388 | (5) |
|
8.3.4 Some other pigments---old and new |
|
|
393 | (2) |
|
8.4 Isomorphism of pigments |
|
|
395 | (3) |
|
9 Polymorphism Of High Energy Materials |
|
|
398 | (31) |
|
|
398 | (2) |
|
9.2 The "alphabet" of high energy molecular materials |
|
|
400 | (2) |
|
|
402 | (27) |
|
9.3.1 Aliphatic materials |
|
|
403 | (13) |
|
|
416 | (13) |
|
10 Polymorphism And Patents |
|
|
429 | (28) |
|
|
429 | (2) |
|
10.2 Novelty and obviousness in crystal form patents |
|
|
431 | (1) |
|
10.3 The scientific perspective |
|
|
432 | (2) |
|
10.3.1 Novelty from a scientific perspective |
|
|
432 | (1) |
|
10.3.2 Obviousness from a scientific perspective |
|
|
432 | (2) |
|
10.4 Some representative crystal form patent litigations |
|
|
434 | (22) |
|
|
434 | (3) |
|
10.4.2 Terazosin hydrochloride |
|
|
437 | (1) |
|
10.4.3 Ranitidine hydrochloride |
|
|
438 | (3) |
|
10.4.4 Paroxetine hydrochloride |
|
|
441 | (2) |
|
|
443 | (4) |
|
10.4.6 Tapentadol hydrochloride |
|
|
447 | (6) |
|
10.4.7 Habit, not form: aspartame |
|
|
453 | (3) |
|
|
456 | (1) |
References |
|
457 | (110) |
Index |
|
567 | |